EBR Systems (ASX:EBR) said it expects US Food and Drug Administration (FDA) approval for its wireless, cardiac resynchronization therapy system WiSE by April, according to a Tuesday filing with the Australian bourse.
Pending regulatory approval, EBR is planning for the commercial launch of the system in the second half of the year, the filing said.
Price (AUD): $2.05, Change: $+0.075, Percent Change: +3.80%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments